Avenue Therapeutics (ATXI) Misses Q1 EPS by 640c

Avenue Therapeutics (NASDAQ: ATXI) reported Q1 EPS of ($15.40), $6.40 worse than the analyst estimate of ($9.00).

For earnings history and earnings-related data on Avenue Therapeutics (ATXI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c